531015 VENMAX

Venmax Drugs & Pharmaceuticals Share Price

 

 

Start SIP in VENMAX

Start SIP

Performance

  • Low
  • ₹24
  • High
  • ₹27
  • 52 Week Low
  • ₹18
  • 52 Week High
  • ₹37
  • Open Price₹27
  • Previous Close₹26
  • Volume699
  • 50 DMA₹27.02
  • 100 DMA₹26.80
  • 200 DMA₹24.99

Investment Returns

  • Over 1 Month + 3.69%
  • Over 3 Month + 32.46%
  • Over 6 Month + 12.99%
  • Over 1 Year + 21.79%

Smart Investing Starts Here Start SIP with Venmax Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Venmax Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 40.2
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 14
  • P/B Ratio
  • 2.4
  • Average True Range
  • 2.14
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.5
  • RSI
  • 47.92
  • MFI
  • 59.78

Venmax Drugs & Pharmaceuticals Financials

Venmax Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹26.44
+ 0.79 (3.08%)
pointer
  • Bearish Moving Average 10
  • Bullish Moving Average 6
  • 20 Day
  • ₹26.62
  • 50 Day
  • ₹27.02
  • 100 Day
  • ₹26.80
  • 200 Day
  • ₹24.99

Resistance and Support

25.9 Pivot Speed
  • R3 29.97
  • R2 28.43
  • R1 27.44
  • S1 24.91
  • S2 23.37
  • S3 22.38

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Venmax Dg.And Pharms. has an operating revenue of Rs. 3.06 Cr. on a trailing 12-month basis. An annual revenue growth of 830% is outstanding, Pre-tax margin of -2% needs improvement, ROE of -0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -17% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 69 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has some relative strength and buyer demand but we want to see further fundamental performance to qualify as a growth stock. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venmax Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-09-02 Amalgamation & A.G.M.
2025-08-16 Others Inter alia, to consider and approve 1. Allotment of Equity Shares pursuant to conversion of Convertible Equity Share Warrants.
2025-07-23 Quarterly Results
2025-05-09 Audited Results

Venmax Drugs & Pharmaceuticals F&O

Venmax Drugs & Pharmaceuticals Shareholding Pattern

23.13%
0%
65.36%
11.51%

About Venmax Drugs & Pharmaceuticals

  • NSE Symbol
  • VENMAX
  • BSE Symbol
  • 531015
  • ISIN
  • INE154G01022

Similar Stocks to Venmax Drugs & Pharmaceuticals

Venmax Drugs & Pharmaceuticals FAQs

Venmax Drugs & Pharmaceuticals share price is ₹26 As on 12 January, 2026 | 02:45

The Market Cap of Venmax Drugs & Pharmaceuticals is ₹13.9 Cr As on 12 January, 2026 | 02:45

The P/E ratio of Venmax Drugs & Pharmaceuticals is 40.2 As on 12 January, 2026 | 02:45

The PB ratio of Venmax Drugs & Pharmaceuticals is 2.4 As on 12 January, 2026 | 02:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23